LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Aandelen Lijst・Roivant Sciences Ltd

Roivant Sciences Ltd

Gesloten

SectorGezondheidszorg

30 0.4

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

29.64

Max

Belangrijke statistieken
By Trading Economics
Inkomsten	669M 356M
Verkoop	521K 2.5M
Winstmarge	14,116.825
Werknemers	721
EBITDA	-65M -354M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+26.61% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.3B 21B
Vorige openingsprijs	29.6
Vorige sluitingsprijs	30

Nieuwssentiment

By Acuity

24%

76%

53 / 344 Rangschikking in Healthcare

Roivant Sciences Ltd Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 mei 2026, 23:08 UTC

Acquisities, Fusies, Overnames

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 mei 2026, 23:06 UTC

Acquisities, Fusies, Overnames

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 mei 2026, 20:53 UTC

Winsten

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 mei 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

29 mei 2026, 20:33 UTC

Marktinformatie

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 mei 2026, 20:11 UTC

Winsten

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mei 2026, 19:47 UTC

Winsten

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 mei 2026, 19:36 UTC

Marktinformatie

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 mei 2026, 19:34 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

29 mei 2026, 19:34 UTC

Marktinformatie

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 mei 2026, 19:22 UTC

Marktinformatie

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 mei 2026, 19:05 UTC

Acquisities, Fusies, Overnames

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 mei 2026, 18:19 UTC

Marktinformatie

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 mei 2026, 18:12 UTC

Acquisities, Fusies, Overnames

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 mei 2026, 18:11 UTC

Marktinformatie

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 mei 2026, 18:10 UTC

Marktinformatie

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 mei 2026, 17:55 UTC

Winsten

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mei 2026, 17:55 UTC

Marktinformatie

NEAR Protocol Nearly Doubles in May -- Market Talk

29 mei 2026, 17:38 UTC

Marktinformatie

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 mei 2026, 17:00 UTC

Winsten

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 mei 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

29 mei 2026, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

29 mei 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

29 mei 2026, 16:02 UTC

Marktinformatie

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 mei 2026, 15:55 UTC

Marktinformatie

Global Equities Roundup: Market Talk

29 mei 2026, 15:55 UTC

Marktinformatie

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29 mei 2026, 15:50 UTC

Acquisities, Fusies, Overnames

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29 mei 2026, 15:50 UTC

Acquisities, Fusies, Overnames

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29 mei 2026, 15:40 UTC

Marktinformatie

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29 mei 2026, 15:20 UTC

Marktinformatie

Canada's Economy Not Looking All That Bright -- Market Talk

Peer Vergelijking

Prijswijziging

Roivant Sciences Ltd Prognose

Koersdoel

By TipRanks

26.61% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 37.83 USD 26.61%

Hoogste 42 USD

Laagste 31.5 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Roivant Sciences Ltd - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Roivant Sciences Ltd - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

53 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.